Overview We are the first publicly traded company to leverage Canton Coin (CC) and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, we also operate clinical-stage biotech research and development programs. From 2022 through late-2025, we primarily operated as a biotechnology company, developing therapeutic candidates in inflammatory and immunologic conditions w...
Q2 FY2026 — expected 2026-09-07
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | CNTN | discussed_in_filing Cybersecurity | |
| topic_mention | CNTN | discussed_in_filing Trusted Computing | |
| topic_mention | CNTN | discussed_in_filing Blockchain & Crypto | |
| topic_mention | CNTN | discussed_in_filing Regulation | |
| topic_mention | CNTN | discussed_in_filing Healthcare & Bio | |
| topic_mention | CNTN | discussed_in_filing Platform & Ecosystem | |
| topic_mention | CNTN | discussed_in_filing Sovereign & Government | |
| topic_mention | CNTN | discussed_in_filing Cybersecurity | |
| topic_mention | CNTN | discussed_in_filing Trusted Computing | |
| topic_mention | CNTN | discussed_in_filing Blockchain & Crypto | |
| topic_mention | CNTN | discussed_in_filing Regulation | |
| topic_mention | CNTN | discussed_in_filing Healthcare & Bio | |
| topic_mention | CNTN | discussed_in_filing Platform & Ecosystem | |
| topic_mention | CNTN | discussed_in_filing Sovereign & Government | |
| topic_mention | CNTN | discussed_in_filing Cybersecurity | |
| topic_mention | CNTN | discussed_in_filing Trusted Computing | |
| topic_mention | CNTN | discussed_in_filing Blockchain & Crypto | |
| topic_mention | CNTN | discussed_in_filing Regulation | |
| topic_mention | CNTN | discussed_in_filing Healthcare & Bio | |
| topic_mention | CNTN | discussed_in_filing Platform & Ecosystem |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-013861 | EDGAR | 81K words |
| 2025-03-26 | 2024-12-31 | 0001641172-25-000654 | EDGAR | — |
| 2024-02-23 | 2023-12-31 | 0001493152-24-007612 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001493152-23-007977 | EDGAR | — |
| 2022-04-01 | 2021-12-31 | 0001493152-22-008703 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001493152-25-021991 | EDGAR | 36K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-023745 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001641172-25-009569 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001493152-24-044063 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001493152-24-030936 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018338 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001493152-23-039775 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001493152-23-027837 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001493152-23-018426 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-031446 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001493152-22-022143 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001493152-22-013424 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001493152-26-013823 | EDGAR | 1K words |
| 2026-03-03 | 0001493152-26-008716 | EDGAR | — |
| 2026-03-03 | 0001493152-26-008651 | EDGAR | — |
| 2026-02-18 | 0001493152-26-007277 | EDGAR | — |
| 2026-02-06 | 0001493152-26-005453 | EDGAR | — |
| 2026-02-02 | 0001493152-26-004650 | EDGAR | — |
| 2026-01-26 | 0001493152-26-003539 | EDGAR | — |
| 2026-01-22 | 0001493152-26-003242 | EDGAR | — |
| 2026-01-20 | 0001493152-26-002787 | EDGAR | — |
| 2026-01-15 | 0001493152-26-002421 | EDGAR | — |
123 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001861657 |
| Ticker | CNTN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report